key: cord-0682501-f6xxeade
authors: Magalhães, D.; Costa, P.; Ferreira, L.; Estevinho, F.
title: OA18.03 LUNGCOVID: SARS-CoV-2 Infection in Patients With Thoracic Tumors - Multicenter Observational Study in Portugal
date: 2021-10-31
journal: Journal of Thoracic Oncology
DOI: 10.1016/j.jtho.2021.08.096
sha: fbbe091f6e125e5a8c9df34a50e2569c0e49a431
doc_id: 682501
cord_uid: f6xxeade

Introduction: Since the beginning of the COVID-19 pandemic, health care system was readjusted and thoracic cancer patients with COVID-19 were studied in international registries. In patients with malignant thoracic neoplasms the differential diagnosis is complex, due to the location of the disease and symptoms related to cancer. Age, smoking status, comorbidities, previous corticotherapy treatment, performance status and stage of thoracic malignancies have been described as prognostic factors. Some registries and series of COVID-19 in thoracic malignancy patients reported mortality rates of 26% (CCC-19), 32% (TERAVOLT), 39% (UKCCMP) and even 47% (Dutch Oncology COVID-19 Consortium). A national survey on the impact of COVID-19 in lung cancer patients' treatment has been presented by the Portuguese Lung Cancer Study Group. However, a national study of COVID-19 patients with thoracic malignancies has not been done. Objectives: To access the frequency and severity of COVID-19 in Portuguese patients with thoracic malignancies, and to study clinical manifestations, intensive care admission and factors associated with a worst outcome. Methods: LUNGCOVID is a multicenter national observational study. Patients with primary thoracic malignancy, age 18-years-old and SARS-CoV-2 infection diagnosed by reverse-transcriptase polymerase chain reaction or antigenic test since March 2020, will be eligible. Clinicopathological characteristics will be accessed by reviewing medical records. The variables to be studied are: age, sex, performance status, smoking habits, presence of comorbidities, previous corticotherapy treatment, factors related to the underlying cancer disease (stage of the disease, histological type), treatments, previous chest radiotherapy, oncologic systemic treatment, COVID-19 symptoms, need of intensive care admission and survival. Results: Section not applicable Conclusion: Section not applicable. Keywords: SARS-CoV-2, thoracic tumors, Outcome

OA18.03 LUNGCOVID: SARS-CoV-2 Infection in Patients With Thoracic Tumors -Multicenter Observational Study in Portugal D. Magalhães, 1 P. Costa, 2 L. Ferreira, 2 F. Estevinho 1 1 Hospital Pedro Hispano, Matosinhos Municipality/PT, 2 Hospital de Braga, Braga/PT Introduction: Since the beginning of the COVID-19 pandemic, health care system was readjusted and thoracic cancer patients with COVID-19 were studied in international registries. In patients with malignant thoracic neoplasms the differential diagnosis is complex, due to the location of the disease and symptoms related to cancer. Age, smoking status, comorbidities, previous corticotherapy treatment, performance status and stage of thoracic malignancies have been described as prognostic factors. Some registries and series of COVID-19 in thoracic malignancy patients reported mortality rates of 26% (CCC-19), 32% (TERAVOLT), 39% (UKCCMP) and even 47% (Dutch Oncology COVID-19 Consortium). A national survey on the impact of COVID-19 in lung cancer patients' treatment has been presented by the Portuguese Lung Cancer Study Group. However, a national study of COVID-19 patients with thoracic malignancies has not been done. Objectives: To access the frequency and severity of COVID-19 in Portuguese patients with thoracic malignancies, and to study clinical manifestations, intensive care admission and factors associated with a worst outcome. Methods: LUNGCOVID is a multicenter national observational study. Patients with primary thoracic malignancy, age 18-years-old and SARS-CoV-2 infection diagnosed by reverse-transcriptase polymerase chain reaction or antigenic test since March 2020, will be eligible. Clinicopathological characteristics will be accessed by reviewing medical records. The variables to be studied are: age, sex, performance status, smoking habits, presence of comorbidities, previous corticotherapy treatment, factors related to the underlying cancer disease (stage of the disease, histological type), treatments, previous chest radiotherapy, oncologic systemic treatment, COVID-19 symptoms, need of intensive care admission and survival. Results: Section not applicable Conclusion: Section not applicable. Introduction: Low-dose computed tomography lung cancer screening has been demonstrated to substantially reduce lung cancer mortality. Lung cancer screening is most effective when applied to high-risk individuals. One approach to determining eligibility is based on categorical age/pack-years/quit-years, which has been exemplified by the United States Preventive Services Task Force (USPSTF2013) eligibility criteria: age 55-80 years, 30 pack-years smoked, and in former smokers quit 15 years. Many comparative studies have found that determining screening eligibility using a validated risk prediction model, such as the PLCOm2012, is more effective. Most of these studies have been retrospective and trial based. The ILST is a large, multinational, population-based prospective study that enrolled individuals for screening if they were USPSTF criteria or PLCOm2012 positive. The aim of this study was to determine which criteria was most sensitive at identifying individuals who would be diagnosed with lung cancer and to determine which selection method led to the most total potential years of life gainable. Methods: A total of 5819 individuals were scan in Canada, Australia, Hong Kong and the U.K. PLCOm2012 risk 1.7%/6y selected exactly the same number of individuals for screening as did the USPSTF2013 criteria. For our analysis, we used this PLCOm2012 threshold for comparisons. Missing data were imputed with multiple imputations. Differences in the proportion of lung cancers detected by USPSTF versus PLCOm2012 were compared using the binomial exact method. Even though it was anticipated that the PLCOm2012 would detect more cancers, they may occur in older individuals with more comorbidities and with shorter life expectancies. Therefore, to make an objective comparison of true benefit between the two approaches, we compared the total number of life years potential gainable in lung cancer patients by each of the criteria. To do this we apply a parametric Weibull survival model which predicted median life expectancy of each participant. The model predictors of all-cause mortality included age, sex, body mass index, number of comorbidities, lung cancer status (no cancer, early stage, or advanced stage lung cancer) and four smoking exposure predictors. The differences in potential life-years were compared between criteria and confidence intervals and p-value were prepared with bootstrap resampling with 1000 re-samplings. Results: After a median follow-up of 2.27 years in both groups, lung cancer was diagnosed in 125 individuals who were USPSTF2013 positive and in 151 individuals who had PLCOm2012 risks 1.7%/6y (p<0.001) (N¼4540 in each group). Those who were PLCOm20121.7%/6y were older (65.7y vs 63.3y) and had more comorbidities (mean 3.0 vs 2.7) than those who were USPSTF positive. In the individuals diagnosed with lung cancer, the difference in total life-years potentially livable if lung cancer death was averted, PLCOm20121.7%/6y minus USPSTF2013 positive) was 258.9 life-years (95% CI 34.2 to 503.3, p¼0.012). Conclusion: In this prospective, multinational, populationbased study, the PLCOm2012 approach selects significantly more individuals diagnosed with lung cancer. In spite of selecting individuals who were older and had more comorbidities, the overall weighted balance of life years potentially liveable if lung cancer deaths were averted significantly favours using the PLCOm2012 criteria. Keywords: screening eligibility criteria, USPSTF PLCOm2012 criteria, Prospective cohort study

Abstracts S881

3 K. Fong, 19 S. Lam 2 1 Health Sciences

13 University Hospital Germans Trias I Pujo, Barcelona/ES, 14 University of Sydney, Sydney/AU, 15 Thoracic Surgery, Vancouver General Hospital